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   bjective: Follicular dendritic cells (FDCs) and interdigitating dendritic cells (IDCs) are dendritic cells found in lymphoid
follicles, reactive follicles and in lymphomas. The goal of this study was to evaluate the presence and distribution of FDCs and IDCs
in oral lymphomas. Material and Methods: Immunohistochemistry reactions were applied to 50 oral lymphomas using the antibodies
anti-CD21, anti-CD35 and anti-caldesmon to FDCs, and anti-S100 protein to IDCs. Caldesmon+/FDCs and S100+/IDCs were
quantified in Imagelab® software. Results: FDCs revealed by CD21 and CD35 were positively stained in two cases of diffuse large
B-cell lymphoma, one MALT lymphoma, and in one case of mantle cell lymphoma. FDCs were immunopositive to caldesmon in all
cases, as well as IDCs to S100 protein. Burkitt lymphoma presented a lower amount of caldesmon+/FDCs and S100+/IDCs than
diffuse large B-cell lymphoma and plasmablastic lymphoma of the oral mucosa type. Conclusions: The microenvironment determined
by neoplastic lymphoid cells in oral lymphomas is responsible by the development and expression of dendritic cells types.
Key words: CD21. CD35. Follicular dendritic cells. Interdigitating dendritic cells. Immunohistochemistry. Lymphoma. Oral
lymphomas.
INTRODUCTION
Dendritic cells (DCs) are non-lymphoid antigen-
presenting cells distributed widely throughout the body and
are distinguishable from macrophages by their lack of both
phagocytic activity and capacity to act as effectors cells.
Morphologically, they present a complex of dendritic
cytoplasmic projections, one or more lobulated nucleoli,
clear cytoplasm with scattered organelles and lack of both
phagocytic activity and capacity to act as effectors cells.
DCs are classified into two groups: B- and T-cells associated
DCs. Follicular dendritic cells (FDCs) represent B-cell
associated DCs. T-cell associated DCs include the
interdigitating dendritic cells (IDCs), indeterminate cells,
Langerhans cells, connective tissue dendritic cells and veiled
cells (dendritic leukocytes)9,22,23.
FDCs are located in B-cell dependent areas of the
lymphoid follicles of secondary lymphoid organs. FDCs
form a three-dimensional meshwork in these B-cell areas.
Functionally, they have an ability to bind and retain antigens
through linking complement and immune complexes for a
long time, and are involved in B-cell proliferation, selection
and differentiation18,21. FDCs can be stained through the
complement receptors, C3d (CD21) and C3b (CD35), and
by the low affinity to IgE receptor (CD23). Also, FDCs are
immunopositive to cell cycle markers, FDCs-associated
antigen (DCR-1; Ki-M4; CNA.42; DR53), intermediated
filament, adhesion molecules, cytokine receptors and to
calcium-bindings proteins (calmodulin; caldesmon; annexin
II; annexin VI and S100 protein α-subunit). The
immunophenotype, as well as ultrastructural features, of
FDCs are variable depending on their distribution in the
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zones of lymphoid follicles. There are few effective
antibodies to identify FDCs in routinely processed paraffin
sections6,8,9,15.
IDCs are located in the T-cell areas of lymph node,
spleen, and thymus, and are related to the function of
presenting antigens to T-cells. IDCs may be detectable by
CD45, class II MHC, and S100 protein2,25. In contrast to
Langerhans cells, IDCs are immunonegative to CD1a5,20.
Due to the relationship between FDCs/B-cell and IDCs/
T-cell, the microenvironment of the neoplastic or reactive
transformation of B- and T-cell produce alterations in
expression of dendritic cells types. Also, a comprehensive
investigation on this subject might provide valuable
information about diagnosis of lymphomas1,3,7,12,14,17,24. Up
to now, there are no studies of DCs in oral lymphomas. The
goal of this study was to evaluate the presence and
distribution of FDCs and IDCs in oral lymphomas. Also,
quantitative analysis of caldesmon+/FDCs and S100+/IDCs
was performed.
MATERIAL AND METHODS
The experimental protocol was approved by the
Committee of Bioethics in Research of the Dental School
of the University of São Paulo, São Paulo, SP, Brazil
(number 150/00).
Tissue Samples
Routinely processed paraffin sections from 50 oral
lymphomas were selected from the files of the Oral
Pathology Service at the University of Sao Paulo, Brazil.
Oral lymphomas were classified according to the World
Health Organization classification/200110 and Colomo, et
al.4 by morphology, immunophenotype, Epstein Barr Virus
detection and IgH gene rearrangement. Representative
samples were diffuse large B-cell lymphoma (DLBCL,
N=17); plasmablastic lymphoma of the oral mucosa type
(PBLOMT, N=11); Burkitt lymphoma (BL, N=15);
extranodal marginal zone B-cell lymphoma of mucosa-
associated lymphoid tissue (MALT lymphoma, N=2); mantle
cell lymphoma (MCL, N=1); extranodal NK/T-cell
lymphoma, nasal type (ETCL, N=3), and peripheral T-cell
lymphoma, unspecified (PTCL, N=1). All cases were
primary of the oral cavity, since physical exam did not
demonstrate signals of disease in other regions of the body.
Immunohistochemistry and Quantitative Analysis
FDCs were characterized with the antibodies anti-CD21,
anti-CD35, and anti-caldesmon. Since caldesmon is also
expressed in the vessel walls, consecutive sections were also
stained with anti-CD34 and both stain were submitted to
quantification with the use of a computerized system
(Imagelab® Software, LIDO, FOUSP, Brazil). Five fields
of each section were selected in a light microscope
(Laborlux; Leitz, Wetzlar, Germany) at 100x magnification.
Images were transferred to a computer monitor with area of
640 x 480 pixels, and the quantification was performed by
subtraction of images. The values of the caldesmon+/FDCs
were obtained through the total of caldesmon+/
immunoexpression minus CD34+/immunoexpression and
expressed in μm2. IDCs were identified by the antibody anti-
S100 protein. Since Langerhans cells also express S100
protein, antibody anti-CD1a was also used in consecutive
sections to exclude the Langerhans cells. S100+/IDCs were
counted in the light microscope (Laborlux; Leitz, 400X
magnification). Ten fields were selected for each case using
an integration reticule and values expressed in mm2. The
statistical analysis was considered only in the DLBCL,
PBLOMT and BL, because the sample of these cases was
sufficient to statistical analysis. This analysis was performed
with Mann-Whitney test and significance statistical was
evaluated at 0.05 level.
A universal automatic system of staining (Dako Auto
Staining®, Dako Corporation, Carpinteria, CA, USA) was
used for immunohistochemistry reactions with the
strepatavidin-biotin standard protocol in 3-μm-thick
sections. The primary antibodies used were: CD21 (DAKO®,
clone 1F8, 1:50, incubation for 40 min at 37oC), CD35
(DAKO®, clone Ber-MAC-CDR, 1:20, incubation for 40
min at 37oC), caldesmon (Novocastra®, clone TD107, 1:50,
incubation for 30 min at 37oC), CD1a (Serotec®, clone 010,
incubation for 30 min at 37oC), S100 protein (DAKO®, clone
Z0311, incubation for 30 min at 37oC), and CD34
(Novocastra®, clone QBEnd/10, 1:50, incubation for 30 min
at 37oC). The sections were submitted to antigen retrieval.
Sections for the reactions with CD21 and CD35 were
immersed in target retrieval solution pH 6.0 (DAKO®,
S1700) heated to 95oC for 30 min. To caldesmon, CD1a,
and CD34, the sections were immersed in citric acid
(SIGMA® CHEMICAL CO., St. Louis, MO, USA) buffer
0.01M, pH 6.0 and heated to 95oC for 30 min. Sections for
the reaction with S100 protein were not submitted to antigen
retrieval. Appropriate positive and negative controls were
used.
RESULTS
The pattern of expression of CD21 and CD35 was the
same. CD21 and CD35 positively stained FDCs in four cases
of oral lymphomas: (a) two cases of DLBCL, (b) one MALT
lymphoma, and (c) on the case of MCL. In the DLBCL,
immunoexpression was observed in pseudofollicular
proliferation centers14,17. The pattern was a sparse and
disrupted meshwork (Figures 1A and 1B). MALT lymphoma
presented FDCs as a dense and confluent meshwork
corresponding to colonized follicles (Figures 1C and 1D).
MCL presented the distribution of FDCs as a loosely
arranged, ill-defined and expanded meshwork (Figures 1E
and 1F).
Caldesmon+/FDCs were present in all oral lymphomas
and appeared as a dense and confluent meshwork (lacy
pattern) among the neoplastic lymphoid cells (Figure 1G).
In cases immunopositive to CD21 and CD35, caldesmon+/
FDCs were coincident with CD21 and CD35 stain. CD34
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FIGURE 1- A- Pseudofollicular proliferation center in the diffuse large B-cell lymphoma (Hematoxylin-eosin, original magnification
x320). B- Follicular dendritic cells stained by CD21 presented as sparse, disrupted meshwork between lymphoid cells of the
pseudofollicular proliferation center of the diffuse large B-cell lymphoma (streptavidin-biotin, original magnification x640). C-
MALT lymphoma presenting reactive follicles (Hematoxylin-eosin, original magnification x100). D- Colonized follicles by follicular
dendritic cells. A meshwork is revealed by CD21 in the MALT lymphoma (streptavidin-biotin, original magnification x320). E-
Mantle cell lymphoma demonstrates a monomorphic lymphoid proliferation with a nodular pattern (Hematoxylin-eosin, original
magnification x100). F- CD21 demonstrates loosely arranged, ill-defined and expanded meshwork of follicular dendritic cells
at the periphery of the mantle cell lymphoma (streptavidin-biotin, original magnification x640). G- Caldesmon revealed a
dense and confluent meshwork of the follicular dendritic cells among lymphoid cells of in a case of diffuse large B-cell
lymphoma (streptavidin-biotin, original magnification x200). H- Interdigitating dendritic cells revealed by S100 protein in one
case of the diffuse large B-cell lymphoma are visualized as irregular spots (streptavidin-biotin, original magnification x320)
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was immunopositive in vessel blood walls distributed
between neoplastic lymphoid cells. No cells immunopositive
to CD1a were observed in the all oral lymphomas. S100+/
IDCs were present in all cases and were scattered amongst
neoplastic lymphoid cells. S100+/IDCs were large cells,
disclosing a round nucleus and irregular cytoplasm (Figure
1H).
Mean values and standard deviation of the quantification
of caldesmon+/FDCs and S100+/IDCs are presented in
Table 1. BL had significantly statistical less caldesmon+/
FDCs and IDC/S100+ than DLBCL. There is not statistical
difference of the caldesmon+/FDCs and S100+/IDCs
quantification between BL and PBLOMT, and DLBCL and
PBLOMT, respectively.
DISCUSSION
FDCs and IDCs are related to B or T and NK-cell
diseases1,3,7,12,14,17,24. More frequently FDCs are evaluated in
reactive follicles and follicular lymphomas because of
microenvironmental similarity between reactive follicles and
follicular lymphomas1,3,7,15,24. Oral lymphomas are almost
exclusively B-cell neoplasm, presenting a diffuse pattern of
growth10. Therefore, the finding of rare CD21+/CD35+/
FDCs is expected. Using antibodies anti-CD21 and anti-
CD35, FDCs were visualized in two cases of DLBCL as a
sparse and disrupted meshwork in neoplastic
pseudofollicular proliferation centers, as demonstrated by
Maeda, et al.14 and Mori, et al.17 that evaluated FDCs in B-
cell neoplasm with a diffuse pattern. Actually, the role of
FDCs is to present antigens to B-cell9,21. In the process of
the antigen-presenting, the activation of complement
receptors C3d (detected by CD21) and C3b (detected by
CD35) takes place in the FDCs19. Therefore, the detection
of FDCs by CD21 and CD35 depends on their activation,
which occurs in reactive follicles, neoplastic pseudofollicular
proliferation centers or in neoplastic follicles of follicular
lymphomas14,17,19.
Morphologically, MALT lymphomas present reactive
follicles10. In the present study, CD21 and CD35 identified
FDCs in the case of MALT lymphoma that exhibited reactive
follicles. Bagdi, et al.1 also verified that stain for CD21,
CD23 and CD35 revealed dense FDCs meshwork in reactive
follicles of seven cases of primary salivary gland or gastric
MALT lymphomas. In the present study, the two cases of
MALT lymphomas were of the salivary gland type. So, in
MALT lymphoma the immunolocalization of the FDCs by
CD21 and CD35 is also dependent on the microenvironment
organized by neoplastic or non-neoplastic lymphoid cells
in the reactive follicles.
MCL typically present a loosely arranged, ill-defined
and expanded meshwork of FDCs at the periphery of the
neoplasm in nodular or diffuse pattern as demonstrated in
the studies of Bagdi, et al.1 and Mori, et al.17. It was also
observed this distribution of FDCs in the case current of
MCL. This finding is important since this pattern of
distribution of FDCs resembles that of the mantle zone of
non-neoplastic lymphoid follicles. Also, the
immunohistochemistry of FDCs in MCL is helpful to
diagnosis of this disease1,17.
In T-cell and NK-cell neoplasm, the CD21+/CD35+/
FDCs are not frequently identified, as in our study1,15,24.
However, angioimmunoblastic T-cell lymphoma presented
a expanded meshwork of CD21+/CD23+/CD35+/FDCs. It
has been suggested that these cells may be not real FDCs,
but rather fibroblastic reticular cells showing overexpression
of CD21, CD23 and CD3510-13.
Immunolocalization of FDCs by caldesmon has not been
widely evaluated. Tsunoda, et al.24 used caldesmon to
evaluate neoplastic follicles of follicular lymphoma and
verified a difference in FDCs immunoexpression in follicular
lymphomas grade I, II and III. Caldesmon stained FDCs in
all the studied oral lymphomas, and FDCs were visualized
Diffuse large B- Plasmablastic lymphoma    Burkitt lymphoma        P values
cell lymphoma     of the oral mucosa  (N=15)
(N=17)  type (N=11)
Caldesmon+/FDCs *, ***15.0±4.3 **, ***12.0±5.0 *, **9.3±2.2 * p=0.0005
(µm2) (mean±SD) ** p=0.37
*** p=0.09
S100+/IDCs (mm2) #, ###2.8±1.5 ##, ###2.6±1.8 #, ##1.6±1.2 # p=0.018
(mean±SD) ## p=0.22
### p=0.7
TABLE 1- Mean values and standard deviation (SD) of the quantification of caldesmon+/follicular dendritic cells (FDCs) and
S100+/interdigitating dendritic cells (IDCs). P values to caldesmon+/FDCs between (*) diffuse large B-cell lymphoma and
Burkitt lymphoma, (**) plasmablastic lymphoma of the oral mucosa type and Burkitt lymphoma and (***) diffuse large B-cell
lymphoma and plasmablastic lymphoma of the oral mucosa type. P values to S100+/IDCs between (#) diffuse large B-cell
lymphoma and Burkitt lymphoma, (##) plasmablastic lymphoma of the oral mucosa type and Burkitt lymphoma and (###)
diffuse large B-cell lymphoma and plasmablastic lymphoma of the oral mucosa type
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as a lacy pattern meshwork among neoplastic lymphocytes.
Also, caldesmon immunoexpression was coincident with
CD21 and CD35 immunoexpression. Thus, in the B-cell
neoplasms (DLBCL, PBLOMT, BL, MALT lymphoma and
MCL) evaluated, caldesmon+/FDCs might represent non-
active FDCs, since active FDCs are immunoexpressed in
follicular microenvironment1,9,21. In the T-cell and NK-cell
neoplasms (ETCL and PTCL) evaluated, caldesmon+/FDCs
also may represent non-active FDCs or fibroblastic reticular
cells with an overexpression of caldesmon. Tsunoda, et al.24
suggested that caldesmon on actin filaments, and
extracellular matrix adhesion receptors on FDCs may be
the main way whereby FDCs twine around extracellular
fibers, contributing to the formation and maintenance of the
meshwork structure. In accordance to Tsunoda, et al.24, may
be that in oral B-cell, T-cell and NK-cell neoplasms
caldesmon is also the major way of the formation and
maintenance of the meshwork structure of FDCs or
fibroblastic reticular cells overexpressing caldesmon.
IDCs were identified by the immunoexpression of S100
protein8,9,22. In order to exclude the possibility of Langerhans
cells, reactions to CD1a were performed in all oral
lymphomas, and were negative in all of them. Thus, it can
be asserted that in the present study the cells positive to
S100 protein were IDCs, as Shinzato, et al.20 and Fonseca,
et al.5 showed.
A few papers have evaluated S100+/IDCs in
lymphomas12. As IDCs are known as antigen-presenting cells
to T-cells, they probably represent active cells in oral
lymphomas, since a few non-neoplastic T-cells are always
present in all B-cell neoplasm. Another possibility is that
IDCs represent a casual feature in lymphomas due to a
favorable microenvironment as also seen is non-neoplastic
lymphoid tissue9,19.
Quantitative analysis of the DCs has never been
performed before. Thus, this study represents the first one
to perform a quantitative analysis of the DCs in lymphomas.
Caldesmon and S100 protein were quantitatively analyzed
because the immunoexpression was consistently present in
all cases. It was observed that BL presented a lower
statistically significant number of caldesmon+/FDCs and
S100+/IDCs than DLBCL. This finding may be related to
the fact that BL is a specific entity and presents a high
proliferation rate, shown by the high mitotic counting,
spontaneous cell death, and high counting (close to a 100%)
of Ki-67 positive cells10. It is well known that FDCs are
related to B-cell proliferation8,9,22. Also, PBLOMT represent
a subgroup of DLBCL that is more frequent in HIV-
patients4,10. PBLOMT may have the same state of cell
proliferation than DLBCL. Meugé-Moraw, et al.16 evaluated
reactive bone marrow biopsies and observed that HIV-
patients did not present differences in FDCs
immunoexpression. Therefore, cell proliferation in oral
lymphomas may be related to the appropriated
microenvironment to development of DCs.
CONCLUSIONS
The microenvironment determined by neoplastic
lymphoid cells in oral lymphomas is responsible by the
development and expression of dendritic cells types.
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